XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 90.51

Change

+2.54 (+2.89)%

Market Cap

N/A

Volume

8.51M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+2.32 (+1.66%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+1.16 (+1.74%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+1.54 (+1.42%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.95 (+2.11%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.57 (+2.60%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.88 (+2.83%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+2.59 (+2.69%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+1.15 (+3.91%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.37 (+2.27%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.63 (+2.91%)

USD 8.55M

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

+0.05 (+0%)

USD 0.06B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.50% 19% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.50% 19% F 29% F
Trailing 12 Months  
Capital Gain 1.43% 29% F 37% F
Dividend Return 0.15% 19% F 1% F
Total Return 1.58% 24% F 24% F
Trailing 5 Years  
Capital Gain -2.95% 24% F 45% F
Dividend Return 0.50% 26% F 2% F
Total Return -2.45% 19% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain -1.91% 14% F 23% F
Dividend Return -1.83% 14% F 14% F
Total Return 0.08% 26% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 31.47% 19% F 33% F
Risk Adjusted Return -5.83% 19% F 17% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.